Askari Tajabadi Nahid, Pakmanesh Hamid, Mirzaee Moghaddameh, Jahani Yunes
Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Department of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran.
Iran J Public Health. 2022 Sep;51(9):2108-2116. doi: 10.18502/ijph.v51i9.10566.
Prostate cancer is the most prevalent malignancy in men. This study was carried out to determine effective factors on the survival rate of patients diagnosed with prostate cancer in Kerman, Iran.
The present study was conducted as a retrospective cohort of 238 patients diagnosed with prostate cancer from 2011 to 2019 in Kerman, Iran. First, the demographic and clinical information of patients were collected. Then, the information on patient survival up to June 2019 was tracked, and their latest statuses of death or survival were recorded. Kaplan-Meier method, log-rank test, and Bayesian Weibull parametric accelerated failure-time model were used for data analysis. Data analysis was carried out by Stata and SAS.
The mean age of patients in the diagnosis was 73.28±10.08 year. The patient's 1, 2, 3 and 5-years of overall survival rates were equal to 78.54%, 65.97%, 56.64% and 49.30, respectively. Patients under surgical therapy relatively held longer survival times compared to the rest of the therapies. Patients under chemotherapy had shorter survival times. Age at diagnosis, occupation, chemotherapy, surgery, education, and smoking variables significantly affected patients' survival (<0.05).
Patients' survival duration increases if the disease is diagnosed at younger ages and its preliminary development stages. Smoking cessation is strongly recommended after diagnosis, as it is associated with a lower survival rate. Patients who underwent radical prostatectomy surgery showed higher survival rates than radiotherapy, hormone ablation, or chemotherapy. Moreover, patients with higher education had more prolonged survival.
前列腺癌是男性中最常见的恶性肿瘤。本研究旨在确定伊朗克尔曼被诊断为前列腺癌患者生存率的影响因素。
本研究为回顾性队列研究,纳入了2011年至2019年在伊朗克尔曼被诊断为前列腺癌的238例患者。首先,收集患者的人口统计学和临床信息。然后,追踪患者截至2019年6月的生存信息,并记录他们最新的死亡或生存状态。采用Kaplan-Meier法、对数秩检验和贝叶斯威布尔参数加速失效时间模型进行数据分析。数据分析通过Stata和SAS软件进行。
患者诊断时的平均年龄为73.28±10.08岁。患者1年、2年、3年和5年的总生存率分别为78.54%、65.97%、56.64%和49.30%。与其他治疗方法相比,接受手术治疗的患者生存时间相对较长。接受化疗的患者生存时间较短。诊断时的年龄、职业、化疗、手术、教育程度和吸烟变量对患者的生存有显著影响(<0.05)。
如果疾病在较年轻的年龄及其早期发展阶段被诊断出来,患者的生存时间会增加。强烈建议诊断后戒烟,因为吸烟与较低的生存率相关。接受根治性前列腺切除术的患者生存率高于放疗、激素消融或化疗。此外,受过高等教育的患者生存时间更长。